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114 Vas. Sophias Ave., 115 27 Athens, GreeceBackground & Aims: Although hepatitis B virus (HBV) transmis- atitis B surface antigen (HBsAg) negative; the so called ‘‘anti-HBc
sion after liver transplantation of grafts from HBsAg-negative,
anti-HBc positive donors is well established, the growing organ
shortage favours the use of such marginal grafts. We systemati-
cally evaluated the risk of HBV infection after liver transplanta-
tion with such grafts and the effect of anti-HBV prophylaxis.
Methods: We performed a literature review over the last
15 years identifying 39 studies including 903 recipients of anti-
HBc positive liver grafts.
Results: Recurrent HBV infection developed in 11% of HBsAg-
positive liver transplant recipients of anti-HBc positive grafts,
while survival was similar (67–100%) to HBsAg-positive recipients
of anti-HBc negative grafts. De novo HBV infection developed in
19% of HBsAg-negative recipients being less frequent in anti-
HBc/anti-HBs positive than HBV naive cases without prophylaxis
(15% vs 48%, p < 0.001). Anti-HBV prophylaxis reduced de novo
infection rates in both anti-HBc/anti-HBs positive (3%) and HBV
naive recipients (12%). De novo infection rates were 19%, 2.6%
and 2.8% in HBsAg-negative recipients under hepatitis B immuno-
globulin, lamivudine and their combination, respectively.
Conclusions: Liver grafts from anti-HBc positive donors can be
safely used, preferentially in HBsAg-positive or anti-HBc/anti-
HBs positive recipients. HBsAg-negative recipients should receive
prophylaxis with lamivudine, while both anti-HBc and anti-HBs
positive recipients may need no prophylaxis at all.
 2009 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
despite the recent advances in liver transplantation (LT), there is
a growing gap between the availability of donors and recipients
on the waiting list. One of the current efforts to overcome the
organ shortage is based on the use of grafts that are from donors
with antibodies against the HBV core antigen (anti-HBc), but hep-Journal of Hepatology 20
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DNA; HBIG, hepatitis B immunoglobulin; LAM, lamivudine.positive donors” [1]. These grafts are rather common in countries
with high or even intermediate prevalence of HBV infection, such
as Asia and the Mediterranean basin. However, anti-HBc positive
liver donors frequently have occult HBV infection, i.e. persistent
liver and/or serum HBV DNA without serologic evidence of active
HBV infection (negative HBsAg with or without positive anti-
HBs). Indeed, several studies in HBsAg-negative subjects have
shown that there is often the detection in the liver of covalently
closed circular DNA (cccDNA) and pregenomic RNA, which is a
marker of ongoing viral replication [2,3], and that may signiﬁ-
cantly increase with the use of post-LT immunosuppression and
in particular with corticosteroids [4]. The liver grafts from anti-
HBc positive donors are currently the main sources of de novo
HBV infection after LT [5,6], which is usually deﬁned by the
development of positive HBsAg and/or detectable serum or liver
HBV DNA in previously HBsAg recipients or even development
of positive anti-HBc in previously HBV naive recipients. However,
the literature documenting the risk of de novo HBV infection and
the effects on the graft is scanty and conﬂicting.
The lack of deﬁnite data explains the wide variation in current
clinical practice. In a survey in the USA in 2001, almost half of
liver transplant physicians reported that they did not use anti-
HBc positive donors in HBV naive recipients [7]. In a more recent
international survey, the responders documented using prophy-
laxis with a nucleos(t)ide analogue (mostly lamivudine, but also
entecavir and adefovir) in the majority of LT recipients of anti-
HBc positive grafts, and 61% also used hepatitis B immunoglobu-
lin (HBIG) (69% in US and 46% in non-US centres, p = 0.03) [8].
In this review, we systematically evaluated all the available
data in order to quantify the impact of using liver grafts from
anti-HBc positive donors and identify the optimal post-LT pro-
phylaxis. We selected two types of recipients: (a) HBsAg-positive
recipients and (b) HBsAg-negative recipients. In particular, we
documented the rates of de novo HBV infection with or without
anti-HBV prophylaxis relative to the donor–recipient HBV sero-
logical status, as well as data on the outcome of de novo post-
LT HBV infection. Our search was based on Medline/PubMed from
January 1994 to december 2008 using the search terms ‘‘hepatitis
B core antibody” and ‘‘liver transplantation”, in papers published
in English. We also conducted a manual search of the reference
lists in the review articles. In total, 133 articles were identiﬁed.
Two authors (E.C., G.V.P.) reviewed the abstracts of these articles
to identify potentially relevant articles. In total, 39 original10 vol. 52 j 272–279
Table 1. Published studies on the prevalence of anti-HBc positivity among
liver donors in different countries.
First author, year [Ref.] Donors, n/N anti-HBc
Country Positive/total Prevalence (%)
Wachs (1995) [42] USA 25/1190 2
Douglas (1997) [12] USA 3/332 3
Dodson (1997) [29] USA 70/2578 3
Shinji (1998) [13] Japan 16/171 9
Yu (2001) [19] USA 15/169 9
Nery (2001) [40] USA 48/724 6
Prieto (2001) [10] Spain 33/268 12
Lee (2001) [14] China 16/30 53
Roque-Alfonso (2002) [21] France 22/315 7
Chen (2002) [16] Taiwan 24/42 57
Lo (2003) [15] China 28/51 55
JOURNAL OF HEPATOLOGYarticles evaluated the rate of de novo HBV infection from anti-HBc
positive donors, were included in the ﬁnal analysis. Data abstrac-
tion was done by one author (E.C.) and any conﬂicts in data
abstraction were arbitrated by discussion with the senior authors
(G.V.P., A.K.B.).
Prevalence of anti-HBc positive liver donors
The rate of anti-HBc positivity in liver donors varies substantially
in different countries reﬂecting the local prevalence of HBV infec-
tion. Thus, the prevalence of anti-HBc is lower in developed coun-
tries ranging from3%to15% [9–13], but itmayexceed50% inhighly
endemic areas [14–16] (Table 1). The prevalence of anti-HBc may
also vary in different areas of the same country and in speciﬁc eth-
nic populations (e.g. it is estimated that 25% of non-Hispanic black
Americans in the USA are anti-HBc positive) [17], and it is usually
higher inolder age individuals,whoare currently increasinglyused
as liver donors [10]. The latter could partly explain the increasing
number of anti-HBc positive cadaveric livers transplanted in the
USA (from 3.9% in 1998 to 4.9% in 2002) [18].
Liver grafts from anti-HBc positive donors to HBsAg-positive
recipients
Nine studies [11,19–26] evaluated the recurrence of HBV infec-
tion in HBsAg-positive recipients of anti-HBc positive liver grafts
(Table 2). During a median follow-up of 27 (19–42) months, post-
transplant HBV infection was observed in 12 (10.5%) of 115 recip-
ients, while median survival ranged from 67% to 100%. In the 12
cases with post-transplant HBV infection, the prophylaxis was:Table 2. Published studies of liver transplantation using anti-HBc positive donors in
First author, year [Ref.] HBsAg positive
Recipients, n Anti-HBV prophylaxis
Yu (2001) [19] 6 HBIG
Manzabeita (2002) [11] 3 HBIG + LAM
Joya-Varquez (2002) [20] 14 HBIG: 5, LAM: 3, HBIG + LAM: 5
Roque-Afonso (2002) [21] 4 HBIG
Nery (2003) [22] 17 LAM: 12, HBIG + LAM: 5
Montalti (2004) [23] 26 HBIG ± LAM
Donataccio (2006) [24] 4 HBIG: 3, HBIG + LAM: 1
Pracoso (2006) [25] 5 HBIG + LAM
Celebi-Kobak (2007) [26] 36 HBIG + LAM
HBIG, hepatitis B immunoglobulin; LAM, lamivudine; NA, not available.
a 2/5 patients under HBIG, 3/3 patients under LAM and 4/5 patients under HBIG + LAM
b 1/3 patients under HBIG.
Journal of Hepatology 201three with HBIG, three with lamivudine and six with HBIG and
lamivudine (HBIG had been discontinued in one at HBV recur-
rence). In one retrospective cohort study [20], recipients of
anti-HBc positive grafts (n = 14.5 with detectable serum HBV
DNA at LT) were compared to recipients of anti-HBc negative
grafts (n = 65). The 14 recipients of anti-HBc positive grafts devel-
oped HBV recurrence more frequently (69.2% vs 35.7%, p = 0.034)
and earlier after LT (2.9 vs 6.4 years, p < 0.005). However, the
patient and graft survival was not different between the two
groups: 60-month survival: 67% vs 68%. In multivariate analysis,
HBV recurrence was independently associated with anti-HBc
donor status (RR: 2.796, p = 0.02) and the use of combined HBIG
and lamivudine prophylaxis (RR: 0.249, p = 0.021), but not the
recipients’ pre-transplant HBeAg status [20].Liver grafts from anti-HBc positive donors to HBsAg-negative
recipients–risk of de novo HBV infection
We identiﬁed 38 relevant studies published as full papers [5,9–
13,16,19,21–50] (Table 3). Nine did not have sufﬁcient data
regarding the serological HBV status in donors and/or recipients
[12,13,23,31,39,43,45,49,50]. Four centres published two studies:
one in Spain [36,37] and three in the USA [22,29,30,34,35,40]
with two of these reports having overlap in study periods
[29,35]. The indication for LT was recorded in 21 studies [10,19,
21–23,25,26,28,30,31,36,37,39,41–45,47,49,50]: HCV cirrhosis
was the most common (25%), followed by alcoholic cirrhosis and
cholestatic liver diseases. The cohort size ranged from 6 to 91
patients with only two studies reporting >50 patients [26,37].
The total number of patients that could be evaluated was 788.
The diagnosis of de novoHBV infection was based on the detec-
tion of HBsAg in previously HBsAg-negative recipients with or
without compatible biochemical or histological ﬁndings in 14
studies [9,10,24,25,27–29,33,35,42,44,45,47,49], or the appear-
ance of HBsAg and/or serum HBV DNA in 19 studies [5,11,13,19,
21,22,26,30–32,34,36–41,43,48]. The presence of HBV DNA was
determined by a hybridization technique in three [10,16,37],
branched-DNA assay in one [11] and polymerase chain reaction
(PCR) assay in the remaining 20 studies [5,9,13,19,21,22,25,
26,28,30–32,34,36,39–41,47–49]. HBV DNA was evaluated in
serum in 17 [9–11,16,22,25,26,30,37,39,40,43–45,47–49] and in
both serum and liver tissue in nine studies [5,13,19,21,28,
31,32,34,41], while it was also evaluated in leukocytes in two
studies [5,34]. In only one study, cccDNA was assessed in liver
tissue [36].HBsAg-positive recipients.
Follow-up (months) HBV recurrence, n (%) Survival (%)
20 0 100
26 1 (33) 67
42 9a (69)
19 0 75
29 0
NA 0
38 1b (25) 100
29 0 67
19 1 (3) 92
.
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Table 3. Published studiesa with liver transplantation using anti-HBc positive donors in HBsAg-negative recipients.b
First author,
year [Ref.]
Anti-HBc (+), anti-HBs () recipients Anti-HBc (+), anti-HBs (+) recipients HBV naive recipients
Patients,
N
Anti-HBV
prophylaxis
Follow-up,
months
De novo
HBV, n
Patients,
N
Anti-HBV
prophylaxis
Follow-up,
months
De novo
HBV, n
Patients
N
Anti-HBV
prophylaxis
Follow-up,
months
De novo
HBV, n
Dickson (1997) [9] 2 None 22 0 None 18 None 22 15
Dodson (1997) [29] 15 None 56 2 7 56 0 25 None 56 18
Dodson (1999) [35] 8 HBIG + LAM 46 0 None 8 HBIG + LAM:
7, HBIG: 1
46 1
Prietro (2001) [10] 3 None 29 0 2 None 29 0 25 None 29 15
Manzabeita
(2002) [11]
11 None 26 2 13 26 0 2 HBIG 26 2
Roque-Afonso
(2002) [21]
4 HBIG 26 0 12 None: 4,
HBIG: 8
22 5
Bacerna (2002) [37] 19 None NA 0 64 NA 10
Chen (2002) [16] 2 LAM: 1,
none: 1
40 0 3 LAM: 2,
none:1
40 0 15 LAM: 13,
none: 2
40 2
Nery (2003) [22] 13 HBIG + LAM:
4, LAM: 9
22 1 23 HBIG + LAM:
6, none: 17
21 0 8 HBIG + LAM:
2, LAM: 6
37 1
Loss (2003)1 [32] 11 HBIG (bolus) +
LAM +
Vaccination
33 0
Suehiro (2005) [28] 4 HBIG + LAM 39 0 3 NA 39 0 15 HBIG + LAM 39 0
De Feo (2005)2 [27] NA None NA 0 NA None NA 0 14 None NA 6
Donataccio
(2006)3 [24]
NA HBIG NA NA NA HBIG NA NA 11 HBIG + LAM: 1, 57 7
Umeda (2006) [47] 38 HBIG 42 9
Celebi-Kobak
(2007) [26]
4 LAM 17 0 3 LAM 28 0 4 LAM 23 0
Takemura
(2007) [33]
2 LAM 31 0 5 HBIG 31 1 9 HBIG 31 1
HBIG, hepatitis B immunoglobulin; LAM, lamivudine; NA, not available.
De novo HBV infection also developed in (a) 1/3 anti-HBs positive recipients under HBIG + LAM + vaccination1 [32]; (b) 0/35 anti-HBc positive and/or anti-HBs positive
recipients under no anti-HBV prophylaxis2 [27], (c) 0/1 anti-HBc positive recipient (unknown anti-HBs status) under HBIG during 11 months of follow-up3 [24].
a Twenty-two studies with <10 patients each (n = 13) [5,19,25,30,34,36,38,40–42,44,46,48] or insufﬁcient data (n = 9) on the serological HBV status of donors and/or
recipients [12,13,23,31,39,43,45,49,50] are not included. De novo HBV infection developed in: (a) 15/57 HBV naive recipients [5,19,25,30,34,38,40–42,48] under no anti-HBV
prophylaxis or LAM ± HBIG ± vaccination, (b) 2/51 anti-HBc positive recipients [anti-HBs negative (1/9), anti-HBs positive (1/20), anti-HBs unknown (0/22)]
[5,19,25,36,38,40,44,46] under no anti-HBV prophylaxis or HBIG ± LAM ± vaccination and (d) 1/25 only anti-HBs positive recipients under LAM plus vaccination [44]. De
novo HBV infection also developed in (a) 15/20 anti-HBc positive recipients (unknown anti-HBs status) under no anti-HBV prophylaxis (15/16) [13] or HBIG + LAM (0/1)
[31] or HBIG plus vaccination (0/3) [49], (b) 0/11 anti-HBs positive recipients under HBIG plus vaccination [49] and (c) 14/95 recipients with unknown anti-HBs/anti-HBc
status under HBIG ± LAM or no prophylaxis (9/67) [12,23,39,43] or HBIG ± vaccination (2/25) [45,50] or vaccination alone (3/3) [50].
b Thirty one recipients (from seven studies [11,16,21,22,24,36,37]) with successful pre-LT vaccination and no post-LT prophylaxis were not included; three (9.6%) of them
developed De novo HBV infection. In addition, 34 recipients (from seven studies [19,24–26,31,33,34]) with successful pre-LT vaccination and HBIG and/or lamivudine post-
LT prophylaxis were not included; none of them developed de novo HBV infection.
ReviewThe immunosuppressive therapy after LT was reported in
detail for each patient in only one study [32], while the immuno-
suppressive regimens with or without the number of patients in
each regimen was reported in 19 studies [10,11,13,16,19,25,
28,30,31,33,34,36,39,43–45,47–49] and no information on the
immunosuppression was provided in 18 studies [5,9,12,21–24,
26,27,29,35,37,38,40–42,46,50]. Tacrolimus or cyclosporine-
based regimens were used in seven [10,11,25,28,34,36,39], only
tacrolimus-based regimens in 10 [13,19,31–33,43,45,47–49] and
only cyclosporine-based regimens in three studies [16,30,44]. In
18 studies [11,13,16,19,25,28,30–34,36,43–45,47–49] steroids
were used as immunosuppressive regimen, while in two studies
[10,39] steroid use was not reported. The plan of steroid with-
drawal (usually tapered and stopped 3–12 months after LT) was
only reported in 10 studies [16,19,31,32,34,44,45,47–49].
In total, de novo HBV infection was observed in 149 (18.9%) of
788 recipients at a median of 24 (5–54) months after LT. Post-
transplant anti-HBV prophylaxis signiﬁcantly affected the proba-
bility of de novo HBV infection, which developed in 28.2% (119/
422) of recipients without, and 8.2% (30/366) of recipients with
post-transplant prophylaxis (p < 0.001). Moreover, de novo HBV
infection developed more rapidly in patients without than with274 Journal of Hepatology 201post-transplant prophylaxis: median onset after LT: 19 vs
35 months (p = 0.05).Probability of de novo HBV infection without post-transplant anti-
HBV prophylaxis
De novo HBV infection after LT with grafts from anti-HBc positive
donors developed in 47.8% (89/186) of HBV naive recipients com-
pared to 15.2% (21/138) of recipients with serological markers of
past HBV infection (p < 0.001) or 9.7% (3/31) of recipients with
successful pre-LT vaccination (p < 0.001). De novo HBV infection
also developed in 8.9% (6/67) of HBsAg-negative recipients with
unknown pre-LT HBV status. The presence of anti-HBs in anti-
HBc positive recipients, which was reported in 106 of 138 such
cases, reduced the probability of de novo HBV infection but did
not eliminate it (Fig. 1).Anti-HBc positive liver grafts to HBsAg-negative recipients with past
HBV infection. (a) HBsAg and anti-HBs negativity with anti-HBc
positivity in recipients. In eight studies [5,9–11,16,29,36,38], de
novo HBV infection developed in 13.1% (5/38) of such recipients
with anti-HBc positive donors during a median follow-up of0 vol. 52 j 272–279
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Fig. 1. Risk of de novo hepatitis B virus (HBV) infection in HBsAg-negative
recipients who received liver grafts from anti-HBc positive donors and no
HBV prophylaxis after liver transplantation (LT) in relation to their HBV
serological status before transplant.
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Fig. 2. Risk of de novo hepatitis B virus (HBV) infection in HBsAg-negative
recipients of liver grafts from anti-HBc positive donors in relation to their
pre-transplant HBV serological status and the use of HBV prophylaxis after
liver transplantation (LT).
JOURNAL OF HEPATOLOGY27 months (0.2–84). (b) HBsAg-negative recipients with anti-HBc
positivity and anti-HBs positivity. In nine studies [5,10,11,16,
22,25,29,36,37], de novo HBV infection was documented in
only 1.4% (1/68) of such recipients with anti-HBc positive donors
during a median follow-up of 26 (0.2–86) months. The anti-HBs
status of the donors was reported in only ﬁve studies including
just 18 HBsAg-negative recipients positive for anti-HBc with or
without positive anti-HBs [5,9,16,36,38], and therefore the
impact of the anti-HBs donors’ status could not be safely
determined.
Anti-HBc positive liver grafts to HBsAg-negative recipients with
successful pre-LT vaccination. Seven studies evaluated the devel-
opment of de novo HBV infection in 31 HBsAg-negative recipients
who developed anti-HBs after HBV vaccination before LT and
received no post-LT prophylaxis [11,16,21,22,24,36,37]. De novo
HBV infection developed in 3 (9.7%) of them during a median
post-LT follow-up of 40 (26–91) months.
Anti-HBc positive liver grafts to HBV naive recipients. During a med-
ian follow-up of 35 months (range: 0.1–91), de novoHBV infection
after LT with grafts from anti-HBc positive donors was detected in
47.8% (89/186) of HBV naive recipients included in 14 studies
[5,9–11,16,21,24,27,29,30,37,38,41,42]. Interestingly, the pres-
ence of anti-HBs in the donors did not affect the probability of de
novo HBV infection in HBV naive recipients. In particular, in eight
studies [5,9,10,16,21,30,38,41] providing the anti-HBs status in
thedonor,de novoHBV infectiondeveloped in 71% (28/39) of recip-
ientswith both anti-HBc and anti-HBs positive donors during a fol-
low-up of 37 (0.2–66) months, and in 65% (20/31) of recipients
with anti-HBc positive but anti-HBs negative donors during a
follow-up of 33 (0.1–91) months (p = 0.70) (Fig. 2).
Post-transplant prophylaxis against de novo HBV Infection
Twenty ﬁve [5,11,16,19,21–26,28,31–35,40,43–50] studies
reported data on post-transplant prophylaxis (HBIG and/or lami-
vudine and/or HBV vaccination) against de novo HBV infection in
366 patients who received liver grafts from anti-HBc positive
donors. HBIG alone was used in 96, lamivudine alone in 75, HBIG
and lamivudine in 104, HBIG and/or lamivudine in 7, post-LTJournal of Hepatology 201vaccination with HBIG and/or lamivudine in 81 and post-LT vac-
cination alone in three cases. De novo HBV infection developed in
7.4% (27/363) of recipients who received HBIG and/or lamivudine
after LT (combined with post-LT vaccination in 81 cases) and in
all 3 cases who received post-LT vaccination alone (p < 0.001).
In particular, de novo HBV infection under HBIG and/or lamivu-
dine was observed signiﬁcantly more frequently in HBV naive
than anti-HBc and/or anti-HBs positive recipients (18/150 or
12% vs 4/153 or 2.6%, p = 0.006). De novo HBV infection also
developed in 8.3% (5/60) of recipients with unknown pre-LT sta-
tus who received HBIG and/or lamivudine with or without post-
LT vaccination (Table 3).
HBIG monoprophylaxis. HBIG (5000 or 10,000 IU intravenously
startingduring the anhepatic phase)wasused asmonoprophylaxis
for varying intervals after LT in eight studies [11,21,24,33,
35,46,47,50] (Table 3). During a median follow-up of 31 months
(range: 3–86), de novo HBV infection developed in 18 (18.7%) of
96 recipients: ﬁve (27%) had discontinued HBIG and another two
(11%) had low serum anti-HBs levels (<50 IU/mL) despite HIBG
administration, at the diagnosis of de novoHBV infection. In partic-
ular, de novo HBV infection under HBIG monoprophylaxis devel-
oped in 27% (17/63) of HBV naive recipients and 5.8% (1/17) of
recipients with past HBV infection (p = 0.10) during a median fol-
low-up of 30 (3–86) and 19 (3–86) months, respectively. In addi-
tion, de novo HBV infection also developed in none of ﬁve
recipients with successful pre-LT vaccination during a median
follow-up of 35 (31–38) months and in none of 11 recipients with
unknown pre-LT HBV status who received post-LT prophylaxis
with HBIG alone. The impact of recipient’s anti-HBs status could
not be determined due to limited data.
Lamivudine monoprophylaxis. Since HBIG has several limitations,
such as high cost, poor compliance and even lowprotection partic-
ularly in HBV naive recipients [11], lamivudine monoprophylaxis
(100–150 mg/day for long periods) against de novo HBV infection
wasalso evaluated in six studies [16,19,22,25,26,40] (Table3).Dur-
ing amedian follow-upof 25 (1–69)months, de novoHBV infection
was observed in 2.6% (2/75) of recipients [1/25 (4.0%) recipients
with past HBV infection, 1/33 (3.4%) HBV naive recipients, 0/17
recipients with successful pre-LT vaccination (p = 0.72)]. Interest-
ingly, the HBV naive recipient with de novo HBV infection devel-
oped it after lamivudine discontinuation (Fig. 3).0 vol. 52 j 272–279 275
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Fig. 3. Risk of de novo hepatitis B virus (HBV) infection in HBsAg-negative
recipients who received liver grafts from anti-HBc positive donors and HBV
prophylaxis after liver transplantation (LT) in relation to their pre-transplant
HBV serological status and the type of post-transplant HBV prophylaxis. HBIG,
hepatitis B immunoglobulin; LAM, lamivudine.
ReviewHBIG and lamivudine combined prophylaxis. Increasing periods of
administration of lamivudine as monotherapy is associated with
increasing rates of HBV resistance, particularly in patients under
immunosuppressive therapy [51]. Thus, the effectiveness of HBIG
and lamivudine combination was evaluated in eight studies
[22,24,28,31,34,35,40,43] (Table 3). Lamivudine (100–300 mg/
day) was given long-term, while HBIG was given short- or long-
term at dosages ranging from 400 IU intramuscularly to
10,000 IU intravenously. During a mean follow-up of 39 (range:
1–86) months, de novo HBV infection was observed in 2.8% (3/
104) of recipients [0/29 recipients with past HBV infection, 0/35
HBV naive recipients, 0/12 recipients with successful pre-LT vacci-
nation, 3/28 (11%) recipients with unknown pre-LT HBV status].
Since the combination of HBIGwith lamivudine is themost widely
used approach for prevention of post-LT HBV recurrence in
patients transplanted for HBV related liver disease, it is often used
as prophylaxis against de novoHBV infection as well [8]. However,
given the lowprobability of de novoHBV infectionwith lamivudine
alone, the beneﬁt of HBIG with lamivudine combined prophylaxis
over monoprophylaxis with lamivudine or perhaps a more potent
antiviral agent is not clear from the current literature.Table 4. Published studiesa on the course of de novo hepatitis B virus (HBV) infectio
First author,
year [Ref.]
Patients with
De novo
HBV, n
Histological ﬁndings HBV the
Prieto (2001) [10] 15 Chronic hepatitis: 12,
mild/massive
necrosis: 1/2
LAM
Segovia (2001) [52] 5 Cirrhosis: 1, moderate
ﬁbrosis: 1
LAM
Manzabeita (2002) [11] 4 Mild hepatitis: 1 HBIG ± L
Roque-Afonso (2002) [21] 5 Mild inﬂammation: 4 LAM
Lee (2004) [50] 3 NA LAM ± H
Jain (2005) [43] 3 NA ADV (YM
Donataccio (2006) [24] 7 Cholestatic hepatitis: 2 LAM
Umeda (2006) [47] 9 Mild inﬂammation/
ﬁbrosis: 5
LAM (in
HBIG, hepatitis B immunoglobulin; LAM, lamivudine; NA, not available.
a Seven reports of 1–2 cases with de novo HBV infection after liver transplantation we
received LAM (n = 10) or HBIG plus LAM (n = 1). All patients had an uneventful course,
adefovir.
b After diagnosis of de novo HBV infection.
276 Journal of Hepatology 201HBV vaccination. HBV vaccination after LT has been evaluated as a
strategy to prevent de novo HBV infection in recipients of grafts
from anti-HBc donors in seven studies [5,32,44,45,48–50]. In six
studies using post-LT vaccination combined with HBIG and/or
lamivudine prophylaxis [5,32,44,45,48,49], de novo HBV infection
developed in 5.7% (4/81) of recipients during a median post-LT
follow-up of 33 months [22–85] (0/19 HBV naive, 2/48 anti-HBc
and/or anti-HBs positive and 2/14 with unknown pre-LT HBV sta-
tus, p = 0.16). In contrast, in the only study in which post-LT HBV
vaccination was given alone, de novo HBV infection was observed
in all three (100%) recipients at 14–20 months after transplant
[50]. Thus, although data are very limited, monoprophylaxis with
HBV vaccination after LT also does not appear to be an effective
prophylactic strategy against de novo HBV infection in recipients
of anti-HBc positive grafts.
Survival of recipients of grafts from anti-HBc positive donors
The 3-year survival of such recipients has been reported to range
between 66% and 100%, if they were HBV naive, and between 89%
and 100%, if they had past HBV infection [5,9–11,13,16,19,21–
26,29–40,43–45,48,49]. The post-transplant survival of recipients
of liver grafts from anti-HBc positive and anti-HBc negative
donors has been comparatively evaluated in only two studies
with contradictory results [9,10]: 4-year survival in recipients
with anti-HBc positive donors was signiﬁcantly lower compared
to recipients with anti-HBc negative donors in a US study (56%
vs 76%, p = 0.005) [9], whereas no signiﬁcant difference in 4-year
survival between these two groups was reported in a similar
Spanish study (68% vs 76%, p > 0.05) [10].
Outcome of patients with de novo HBV infection
Histological characteristics
Histological characteristics were available in 13 studies including
68 patients [9,10,13,21,22,24,30,32,39,41,42,47,52], but liver
biopsies at diagnosis of de novo HBV infection were performed
in only six studies and only 41 patients [10,21,22,24,32,39] (Table
4). Mild inﬂammation without ﬁbrosis was found in 33, mild to
moderate inﬂammation with portal or bridging ﬁbrosis in 12,n after liver transplantation.
Course of de novo HBV infection Follow-up,b
months
rapy
Survival: 80% – 3 deaths
(recurrent HCV: 1, lymphoma:
1, sepsis: 1)
37
Survival: 100% 8
AM LAM resistance: 1 (mild hepatitis) 19–63
LAM resistance after 7–16 months: 5 12
BIG Stable course NA
DD mutation) 1 death (fulminant liver failure) NA
2 deaths (cholestatic HBV: 1, sepsis: 1) 27
six patients) Disappearance of HBsAg in 5
patients after 4.6 months under LAM
21
re not included [22,32,33,36,38,39,44]. In total, 11 recipients (severe hepatitis: 1)
except for one patient [36] with poor response to LAM treated with addition of
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anti-HBc positive and/or 
anti-HBs positive  
recipients
HBsAg positive 
recipients
anti-HBc+
anti-HBs+
anti-HBc+
anti-HBs -
anti-HBc -
anti-HBs+
nonePost-LT prophylaxis: LAM LAM LAM
HBIG
+
LAM
anti-HBc negative and
anti-HBs negative 
recipients
ANTI-HEPATITIS B CORE POSITIVE LIVER GRAFTS 
Fig. 4. Proposed algorithm for allocation and management of anti-HBc positive liver grafts. Such grafts should be ﬁrst offered to HBsAg positive, then to anti-HBc and/
or anti-HBs positive and lastly to HBV naive (both anti-HBc and anti-HBs negative) recipients. LT, liver transplantation; HBIG, hepatitis B immunoglobulin; LAM,
lamivudine.
JOURNAL OF HEPATOLOGYsevere inﬂammation and/or cirrhosis in nine, cholestatic hepatitis
in three, and non-speciﬁc ﬁndings in 11 patients.
Course of de novo HBV infection under antiviral therapy
The data on the treatment of de novoHBV infection is notwell doc-
umented, but there are no grounds to expect the efﬁcacy of treat-
ment to be different from that of post-transplant HBV recurrence
[51,53]. Only a total of 62 patients are reported. Lamivudine was
used in the ﬁrst 15 studies (combined with HBIG in three) with
good initial response [10,11,21,22,24,32,33,36,38,39,43,44,47,
50,52], but lamivudine resistance developed in all ﬁve cases after
7–16 months in one study [21] (Table 4). Salvage adefovir therapy
was effective in three patients with lamivudine resistance [36,43].
Given the poor resistance proﬁle of long-term lamivudine mono-
therapy, newer and more potent nucleos(t)ide analogues with
lowprobability of resistance need to be used in this setting despite
the lack of data.
Survival of patients with de novo HBV infection
The survival has been reported to range between 66% and 100%
during a median follow-up of 48 (3–80) months in 19 studies
providing relevant data [5,10,13,16,21,24,30,32,33,35–39,41,42,
47,50,52]. In 14 studies, survival was 100% with a median fol-
low-up of 32 (3–80) months [5,16,21,30,32,33,35–39,47,50,52].
In one study, the outcome of de novo HBV infection was signiﬁ-
cantly better than that of recurrent HBV infection: 3-year sur-
vival: 95% vs 60%, (p = 0.03) [41]. In the latter study, the causes
of death were related to HBV infection in only 2 of 21 non-survi-
vors with de novo HBV infection and two additional patients
underwent re-LT due to HBV infection.Conclusions
As the number of patients on LT waiting list continues to grow,
the demand for donor organs increases. Thus, the expansion of
donor criteria and the inclusion of marginal livers, such as those
from anti-HBc positive individuals will be very helpful. In fact,
such donors represent a signiﬁcant source of transplantable
organs, particularly in countries with high or intermediate HBV
prevalence [54]. The risk of de novo post-LT HBV infection isJournal of Hepatology 201the major limitation of using liver grafts from anti-HBc positive
donors, since occult HBV infection in the donor liver may be reac-
tivated in the recipient due to post-LT immunosuppressive ther-
apy. Such liver grafts may be ﬁrst offered to patients transplanted
for HBV related liver disease, as they require life-long anti-HBV
prophylaxis in any case (Fig. 4). Although in one study HBsAg-
positive recipients of anti-HBc positive liver grafts were sug-
gested to have more frequent and earlier HBV recurrence com-
pared to those of anti-HBc negative liver grafts [20], the risk of
HBV recurrence was not reported to be high in several other stud-
ies and the donor’s anti-HBc status has not been found to affect
the post-transplant survival.
Many centres now use grafts from anti-HBc positive donors for
HBsAg-negative recipients. Since the probability of such de novo
HBV infection is substantially lower in anti-HBc and/or anti-HBs
positive compared to HBV naive recipients (15% vs 48%), it is rea-
sonable to recommend that liver grafts from anti-HBc positive
donors should be preferentially directed to HBV exposed LT candi-
dates (Fig. 4). In the latter, the presence of anti-HBs seems to pro-
tect from de novo HBV infection and both anti-HBc and anti-HBs
positive recipients seem to represent a group that can safely
receive anti-HBc positive liver grafts without any post-transplant
HBV prophylaxis (probability of de novo HBV infection <2%). Pre-
LT vaccination alone does not appear to be an effective strategy,
as de novo HBV infection after LT developed in 10% of successfully
vaccinated recipients without any post-LT prophylaxis. However,
HBV vaccination should be offered to all naive HBV patients early
in the course of non-HBV chronic liver disease (i.e. in the pre-cir-
rhotic stage), even though additional anti-HBV prophylaxis will
be needed in cases of LTwith grafts from anti-HBc positive donors.
Because of lackof data, no conclusions canbedrawnon the effect of
the donor’s anti-HBs status, which could theoretically reduce the
risk of transmission even further.
The use of post-transplant prophylaxis with HBIG and/or lam-
ivudine reduces the overall probability of de novo HBV infection
in both HBV naive (from 48% to 12%) and anti-HBc and/or anti-
HBs positive recipients of anti-HBc positive grafts (from 15% to
3%). According to a recent survey reﬂecting current clinical prac-
tice, prophylaxis with lamivudine and often HBIG is usually used
after LT with anti-HBc positive grafts, but it is less likely to be
used in anti-HBs positive recipients [8]. Although there are no0 vol. 52 j 272–279 277
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good data from single studies on the optimal anti-HBV prophy-
laxis, several conclusions can be drawn based on all the studies
we have reviewed. First, monoprophylaxis with HBIG or HBV vac-
cination after LT is an ineffective strategy, as it is associated with
approximately 20% and 100% risk of de novo HBV infection.
Monoprophylaxis with lamivudine appears to offer satisfactory
protection with <3% risk of de novo HBV infection, although it
should be noted that the number of reported cases is still small
(n = 75) and the follow-up relatively short (approximately
2 years). The combination of HBIG and lamivudine is often used
empirically in this setting, because of its proven beneﬁt in pre-
venting HBV recurrence after LT for HBV related liver disease
[51,55]. However, this combination does not seem to provide a
clear beneﬁt compared to lamivudine monoprophylaxis in liver
transplant HBsAg-negative patients who receive anti-HBc posi-
tive grafts. In fact, the rationale for HBIG use is unclear, as there
are no circulating HBsAg coated virions in HBsAg-negative recip-
ients to be neutralised by HBIG. Whether monoprophylaxis with
a new nucleos(t)ide analogue with better resistance proﬁle might
be a more cost-effective long-term approach in all or in subsets of
such transplant patients also remains to be determined. Given
the relatively low numbers of cases, the different subgroups of
donor–recipient matching with anti-HBc/anti-HBs status and
the varied prophylactic interventions, multicentre studies will
be required in order to provide evidence-based data.
If de novo post-LT HBV infection develops, antiviral treatment
is mandatory. Although documentation of transplant details and
outcomes is scanty, it is reasonable to think that the efﬁcacy of
treatment is similar to that of post-transplant HBV recurrence.
Given the poor resistance proﬁle of long-term lamivudine mono-
therapy and the low potency of adefovir, both entecavir and ten-
ofovir may be the agents of choice today, despite the current lack
of relevant data. Entecavir has the advantage of not being neph-
rotoxic and tenofovir has the advantage of better long-term efﬁ-
cacy in cases of lamivudine resistance.
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